Novo sees low single-digit sales growth hit from drug price pact

Novo Nordisk (NVO) confirmed it has agreed with the U.S. government to lower drug prices beginning in 2026 and expand patient access and affordability for semaglutide medicines, including Wegovy and Ozempic, in Medicare Part D and Medicaid and in direct-to-patient cash channel. Medicare Part D coverage for anti-obesity medicines will be enabled through a pilot program designed to cover a majority of Part D beneficiaries. In addition, Novo Nordisk is expected to receive a three-year tariff exemption. Novo Nordisk currently expects an estimated direct, negative low single-digit impact on global sales growth in 2026. Implementation is expected to begin in 2026.